News

2017
July 11, 2017

Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

[…]
June 1, 2017

OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals

[…]
January 25, 2017

China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study

[…]
January 20, 2017

OBI Pharma holds EOP2 meeting with US FDA

[…]
January 10, 2017

OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.

[…]
2016
November 30, 2016

OBI Pharma Awarded Level-A Recognition for TIPS Management

[…]
November 23, 2016

OBI Pharma Granted OBI 833 Patents for Taiwan and Australia

[…]
October 26, 2016

OBI Pharma Sponsors Successful Adagloxad Simolenin (OBI-822) Symposium at ESMO

[…]
September 6, 2016

Legal Statement-OBI’s Attorneys Decide to Take Further Actions against Next Magazine

[…]
September 6, 2016

OBI Pharma to Sponsor Adagloxad Simolenin Satellite Symposium at the 2016 ESMO Annual Meeting

[…]
September 3, 2016

Michael Chang: “the U.S. Department of Justice Had Already Proven My Innocence”

[…]
August 11, 2016

Dr. Nathan Chen leaves OBI Pharma; Accepts New Role on Company’s Medical Advisory Board

[…]
July 27, 2016

Quick Takes on Promising New Approaches to Treating Breast Cancer

[…]
July 26, 2016

ASCO KOL interviews: Dr. Hope Rugo/Dr. James C. Paulson

June 5, 2016

OBI Pharma Presents Data for Novel Investigational OBI-822/OBI-821 in Patients with Metastatic Breast Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

[…]
June 2, 2016

Test News article

[…]
May 19, 2016

OBI’s Abstract at ASCO 2016: Randomized Phase 2/3 Trial of Active Immunotherapy With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer

[…]
May 19, 2016

OBI Pharma to Present New Data at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

[…]
May 13, 2016

Company Position Statement Regarding Recent Investigation of Senior Executives

[…]
March 31, 2016

OBI Pharma Announces Decision By ASCO to Accept its Abstract for Oral Presentation at ASCO’S 2016 Annual Meeting

[…]
February 21, 2016

OBI Pharma Reports Topline Results from OBI-822/821 Randomized Controlled Phase 2/3 Clinical Trial in Patients with Metastatic Breast Cancer

[…]
2014
December 8, 2014

Cancer Active Immunotherapy OBI-822 Mechanelism Action

December 8, 2014

Introduction of OBI PHARMA, INC.’s

July 21, 2014

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

[…]
January 15, 2014

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

[…]
2013
October 8, 2013

OBI Pharma Announces NT$ 1.5 Billion Capital Infusion

[…]
July 26, 2013

OBI Pharma Wins the “Greatest Potential Award” at the 2013 Outstanding Biotech Awards

[…]
February 7, 2013

OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.

[…]
January 31, 2013

OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

[…]
January 18, 2013

OBI’s company English name official renamed OBI Pharma, Inc.

2012
August 8, 2012

Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

[…]
July 20, 2012

DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD

[…]